https://scholars.lib.ntu.edu.tw/handle/123456789/589576
標題: | Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6-35 Months of Age: Results from a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging Study | 作者: | Kim J.H. Drame M. Puthanakit T. Chiu N.-C. Supparatpinyo K. LI-MIN HUANG Chiu C.-H. Chen P.-Y. Hwang K.-P. Danier J. Friel D. Salaun B. Woo W. Vaughn D.W. Innis B. Schuind A. |
關鍵字: | AS03; children; dose finding; H5N1; influenza vaccine | 公開日期: | 2021 | 出版社: | Lippincott Williams and Wilkins | 起(迄)頁: | E333-E339 | 來源出版物: | Pediatric Infectious Disease Journal | 摘要: | Background: This phase 2 observer-blind, randomized, multicenter, dose-ranging study evaluated immunogenicity and safety of different formulations of an AS03-adjuvanted H5N1 influenza vaccine in children 6-35 months of age. Methods: One hundred eighty-five children randomized into 5 groups [1.9 ?g hemagglutinin (HA)/AS03B, 0.9 ?g HA/AS03C, 1.9 ?g HA/AS03C, 3.75 ?g HA/AS03Cor 3.75 ?g HA/AS03D] were to receive 2 doses administered 21 days apart (primary vaccination). AS03 was classified by amount of DL-a-tocopherol, with AS03Bthe highest amount. One year later, all subjects were to receive unadjuvanted 3.75 ?g HA as antigen challenge. Immunogenicity was assessed 21 days after primary vaccination (day 42) and 7 days after antigen challenge (day 392). Immunogenicity-fever index, based on hemagglutination inhibition and microneutralization antibody titers at day 42 and fever 7 days after each vaccination, was used to guide the selection of an acceptable formulation. Results: After primary vaccination, formulations elicited strong homologous immune responses with all subjects' hemagglutination inhibition titers =1:40 post-vaccination. Immunogenicity-fever index based on hemagglutination inhibition and microneutralization assays showed that 1.9 ?g HA/AS03Branked the highest. Antibody levels persisted >4 times above baseline 12 months after primary vaccination with all formulations (day 385). Antibodies increased >4-fold after antigen challenge (day 392/day 385) with 1.9 ?g HA/AS03B, 0.9 ?g HA/AS03Cand 1.9 ?g HA/AS03Cformulations. Overall per subject, the incidence of fever ranged from 28.6% (3.75 ?g HA/AS03D) to 60.5% (1.9 ?g HA/AS03B). Conclusions: All formulations were highly immunogenic and demonstrated acceptable safety profiles, with the 1.9 ?g HA/AS03Bproviding the most favorable balance of immunogenicity versus reactogenicity for use in children 6-35 months of age. ? 2021 Lippincott Williams and Wilkins. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112751314&doi=10.1097%2fINF.0000000000003247&partnerID=40&md5=ec910cd8ff42c2e43abe8990e6aae4f5 https://scholars.lib.ntu.edu.tw/handle/123456789/589576 |
ISSN: | 0891-3668 | DOI: | 10.1097/INF.0000000000003247 | SDG/關鍵字: | immunological adjuvant; influenza vaccine; virus antibody; blood; clinical trial; controlled study; dose response; female; human; immunology; infant; influenza; Influenza A virus (H5N1); male; multicenter study; phase 2 clinical trial; preschool child; randomized controlled trial; vaccine immunogenicity; Adjuvants, Immunologic; Antibodies, Viral; Child, Preschool; Dose-Response Relationship, Immunologic; Female; Humans; Immunogenicity, Vaccine; Infant; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Male |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。